

Relationship between angiotensin-like-protein-2 levels and anti-mullerian hormone levels in polycystic ovary syndrome of reproductive age

Dyan Asih Rachmawati^{1*}, Ashon Sa'adi², Budi Utomo², Arif Tunjungseto²

ABSTRACT

Introduction: Polycystic Ovary Syndrome (PCOS) is the most prevalent metabolic disease affecting reproductive-age women and is often present with insulin resistance. Angiotensin-like-protein-2 (ANGPTL2) is an angiogenic factor influencing insulin resistance in PCOS, manifesting in the anti-mullerian hormone (AMH). There are no previous studies regarding the relationship between ANGPTL2 levels and AMH in PCOS. The study aims to analyse the relationship between ANGPTL2 and AMH levels in PCOS and to compare ANGPTL2 and AMH levels between PCOS phenotypes.

Methods: This cross-sectional study on 43 women aged 18-40 diagnosed with PCOS according to the Rotterdam criteria. Subjects were recruited consecutively and categorized into four PCOS phenotypes. Serum levels of ANGPTL2 and AMH were measured and analysed by correlation and comparison test using SPSS 26.

Results: A total of 43 PCOS samples were included in the study within 4 months. Based on the severity, phenotype A (anovulation, hyperandrogenic and polycystic ovaries) showed the highest levels of ANGPTL2 and AMH. There was no significant difference in ANGPTL2 levels between the PCOS phenotypes. There was a significant difference in AMH levels between phenotypes, where the highest value was between phenotypes A and B. There was a positive correlation between ANGPTL2 and AMH levels.

Conclusion: There is a positive relationship between ANGPTL2 and AMH serum levels. The ANGPTL2 serum levels were not significantly different. In contrast, the AMH serum levels significantly differed across the four PCOS phenotypes, with the highest level found in phenotype A.

Keywords: angiotensin-like protein 2, Anti-Mullerian hormone (AMH), phenotype, polycystic ovary syndrome.

Cite This Article: Rachmawati, D.A., Sa'adi, A., Utomo, B., Tunjungseto, A. 2023. Relationship between angiotensin-like-protein-2 levels and anti-mullerian hormone levels in polycystic ovary syndrome of reproductive age. *Bali Medical Journal* 12(1): 861-865. DOI: 10.15562/bmj.v12i1.4201

¹Resident in Training-1 Departement/SMF of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Hospital, Surabaya, Indonesia;

²Staff of Department/KSM of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Hospital, Surabaya, Indonesia;

*Corresponding author:

Dyan Asih Rachmawati;
Department: Resident in Training-1
Departement/SMF of Obstetrics and
Gynecology, Faculty of Medicine,
Universitas Airlangga – Dr. Soetomo
General Hospital, Surabaya, Indonesia;
dyanasihrachmawati@gmail.com

Received: 2022-12-15

Accepted: 2023-01-29

Published: 2023-02-26

INTRODUCTION

Polycystic ovary syndrome (PCOS) is the most common metabolic disease in women of reproductive age. The prevalence of PCOS is known to be 5-10% and around 15-20%, according to the European Society for Human Reproduction and Embryology/American Society for Reproductive.¹⁻⁴ Insulin resistance is the most common condition in PCOS patients, which can be measured by the Homeostatic Model Assessment of Insulin Resistance (HOMA IR). Angiotensin-like-protein-2 (ANGPTL2) is an angiogenic factor that plays a role in the pathogenesis of insulin resistance in the PCOS condition. Anti-mullerian hormone (AMH) is a hormone

that is expressed in small pre-antral and antral follicles. The increased number of PCOS is closely related to impaired folliculogenesis.^{5,6}

The diagnosis of PCOS was made according to the Rotterdam criteria, where at least 2 of 3 criteria were found: anovulation, hyperandrogenism and morphology of polycystic ovaries. Grouped into phenotype A, if all three symptoms are present, phenotype B (anovulation and hyperandrogenic), phenotype C (hyper androgen and polycystic ovarian morphology) and phenotype D (anovulation and polycystic ovarian morphology). Angiotensin-like-protein-2 is an angiogenic factor that mediates the occurrence of insulin

resistance through obesity (chronic low-grade inflammation) and without obesity (serine phosphorylation) pathways. In both conditions, there can be an increase in ANGPTL2 serum levels and insulin resistance occurs. The anti-mullerian hormone is a good biochemical marker of ovarian function, produced by preantral and small antral follicle's granulosa cells. In PCOS, AMH levels will increase and positively correlate with ovarian morphology.^{5,6} The study aims to analyse the relationship between ANGPTL2 serum levels and AMH serum levels in PCOS and the differences between ANGPTL2 serum levels and AMH serum levels in PCOS based on their phenotype.

Table 1. Patients Demographics.

Demographic	Phenotype A (%); (min-maks)	Phenotype B (%); (min-maks)	Phenotype C (%); (min-maks)	Phenotype D (%); (min-maks)	Total (%); (min-maks)
Age (year old)	27.82±4.38*	29.71±4.46	29.29±5.28	29.92±2.71	28.95±4.12
Median	28 (19-34)**	31 (24-36)	30 (22-39)	29 (26-34)	29 (19-39)
18-25	3 (7)	2 (4.7)	1 (2.3)	0	6 (14)
26-30	9 (20.9)	1 (2.3)	4 (9.3)	7 (16.3)	21 (48.8)
31-35	5 (11.6)	3 (7)	1 (2.3)	5 (11.6)	14 (32.6)
35-40	0	1 (2.3)	1 (2.3)	0	2 (4.7)
Total	17 (39.5)	7 (16.3)	7 (16.3)	12 (27.9)	43 (100)
Residence					
Surabaya	11 (25.6)	6 (14)	2 (4.7)	10 (23.3)	29 (67.4)
Out of Surabaya	6 (14)	1 (2.3)	5 (11.6)	2 (4.7)	14 (32.6)
Total	17 (39.5)	7 (16.3)	7 (16.3)	12 (27.9)	43 (100)
BMI					
Mean	31.08±4.9*	30.49±6.34	23.27±1.70	25.29±5.48	28.1±5.82
Median	30.3 (21.5-37.8)**	28.65 (21.23-40.18)	22.66 (21.08-26.04)	24.33 (18.67-37.88)	27.73 (18.67-40.18)
18.5-24.9	2 (4.7)	1 (2.3)	6 (14)	7 (16.3)	16 (38.1)
25-29.9	6 (14)	3 (7)	1 (2.3)	3 (7)	13 (31)
30-34.9	4 (9.3)	1 (2.3)	0	1 (2.3)	6 (14.3)
35-39.9	5 (11.6)	1 (2.3)	0	1 (2.3)	7 (16.3)
> 39.9	0	1 (2.3)	0	0	1 (2.4)
Total	17 (39.5)	7 (16.3)	7 (16.3)	12 (27.9)	43 (100)
Infertility					
Not married yet	3 (7)	0	1 (2.3)	0	4 (9.3)
No infertility	0	1 (2.3)	0	1 (2.3)	2 (4.7)
Primary infertility	10 (23.3)	6 (14)	5 (11.6)	8 (18.6)	29 (67.4)
Secondary infertility	4 (9.3)	0	1 (2.3)	3 (7)	8 (18.6)
Total	17 (39.5)	7 (16.3)	7 (16.3)	12 (27.9)	43 (100)
ANGPTL2					
Mean	1.92±0.69*	1.30±0.28	1.48±0.43	1.64±0.41	1.67±0.56
Median	1.82 (0.65-3.1)**	1.35 (0.84-1.62)	1.53 (0.72-2.13)	1.55 (0.83-2.16)	1.59 (0.65-3.10)
AMH					
Mean	10.31±4.18*	4.18±0.46	7.02±1.35	7.51±3.03	7.99±3.77
Median	9.61 (5.46-21.52)**	4.15 (3.74-5.06)	6.73 (5.21-8.84)	6.10 (4.12-11.92)	6.73 (3.74-21.52)

Table 2. Normality Test (Shapiro-Wilk).

Variable	n	p
ANGPTL2	43	0.179
AMH	43	<0.001

METHODS

Study Design

This analytic observational study with a cross-sectional design was conducted at the obstetrician-gynaecologists private practice clinic and Dr. Soetomo Hospital in Surabaya.

Participants and Settings

The patients diagnosed with polycystic ovary syndrome according to the Rotterdam criteria between August until November 2022 who met the inclusion and exclusion criteria. Subjects were recruited by consecutive sampling and

categorised into four PCOS phenotypes, then serum levels of ANGPTL2 and AMH were measured. Eligibility criteria for the participants in this study are patients with polycystic ovary syndrome according to the Rotterdam criteria aged 18-40 years. The exclusion criteria are the patient's history and clinical complaints about vascular abnormalities, kidneys, livers, tumours and who had been threatened before.

Table 3. Spearman Correlation Test.

		AMH
ANGPTL 2	Correlation Coefficient	0.355
	<i>p</i> (2-tailed)	0.019
	N	43

Table 4. Anova Test.

	n	F	<i>p</i>
Between Groups	3	2.651	0.062
Within Groups	39		
Total	42		

Table 5. Kruskal Wallis Test.

Phenotype	AMH Average	<i>p</i>
A	10.308	<0.001
B	4.177	
C	7.017	
D	7.509	

Table 6. Mann Whitney Test.

Group	Different Average	<i>p</i>	
A and B	6.131	<0.001	Significantly different
A and C	3.291	0.033	Significantly different
A and D	2.799	0.057	Not Significantly different
B and A	-6.131	<0.001	Significantly different
B and C	-2.840	0.002	Significantly different
B and D	-3.332	0.002	Significantly different
C and A	-3.291	0.033	Significantly different
C and B	2.840	0.002	Significantly different
C and D	-0.492	0.735	Not Significantly different

Sample Size

The sample size was calculated using a cross sectional study formula based on a proportion of 50% and an error of 0.15. The sample size was 43 patients, collected using a consecutive sampling technique.

Test Methods

The PCOS patient list from 2021 until 2022, after participants agreed to informed consent, demographic data were collected from anamnesis, the physical examination to measure BMI, Ferriman Galleway Score and ovarian morphology USG. ANGPTL2 and AMH serum have been collected from intravenous serum as much as 5 ml.

Analysis

All subjects were given the same treatment, performed anamnesis, physical examination and ultrasound to assess the morphological picture of the ovaries. Then a 5 ml venous blood sample was taken

and the ANGPTL2 and AMH levels were measured. The data were analysed using SPSS software version 26.

RESULTS

Demographics

In this study, there were 43 patients with demographic characteristics shown in [Table 1](#) majority of the patients were 26-30 years old. The average body mass index (BMI) was 31.08 ± 4.9 kg/m². The most common BMI categories were obesity and overweight (27 people (62.8%)). Based on the result, most research subjects have phenotype A (17 respondents (40.5%)), followed by phenotypes D, B and C of 12 respondents (27.9%), 7 respondents (16.3%) and 7 respondents (16.3%). The available data shows the most phenotype, namely phenotypes A (39.5%). The highest BMI in phenotype A is 31.08 ± 4.9 . The median AMH level in the PCOS group

was 9.61 (5.46-21.52) ng/ml. The highest mean ANGPTL2 level and median AMH level results for phenotype A were 1.92 ± 0.69 and 9.61 (5.46-21.52).

Correlation Study

Based on the results in [Table 2](#), the *p*-values of ANGPTL2 and AMH level data were 0.179 and <0.001, respectively. The probability value of AMH data is smaller than the 0.05 significance level and the probability value of ANGPTL2 data is greater than the 0.05 significance level. This means that the assumption of normality is not fulfilled.

[Table 3](#) shows a significant relationship between ANGPTL2 and AMH (*p* = 0.019), which refers to the basis for decision-making, with the result that H₀ was rejected. The correlation coefficient is 0.355 and has a positive value indicating an adequate and unidirectional relationship.

Comparative Study

Based on [Table 4](#), the probability value is 0.062. This probability value is greater than the significance level of 0.05. Referring to the basis of decision-making, H₀ is accepted or there is no significant difference in the average ANGPTL2 between phenotypes, so the Post-hoc test is unnecessary.

Based on the Kruskal Wallis test results in [Table 5](#), the probability value is <0.001. The probability value is smaller than the 0.05 significance level. Referring to the basis of decision-making, H₀ is rejected or there is a significant difference in the average AMH for each phenotype. The Mann-Whitney test was performed to compare each phenotype's mean difference in AMH level. The basis for decision-making is the same as the Kruskal-Wallis test. [Table 6](#) shows the most significant differences in phenotype A and B groups, but there were no significant differences between phenotypes A and D; C and D phenotypes.

DISCUSSION

Based on the result, most research subjects have phenotype A. Previous studies, such as in Wiweko et al., found phenotype A in 31.2% of subjects, Gursu et al. in 44.8% of subjects, and Gupta et al. in 38% of subjects. Ozay et al. found phenotype A

as 33.4%, and Carmina and Lobo as much as 54% of their total PCOS respondents. This result is consistent with the existing theory of hyperandrogenic conditions. Oligo or anovulation and polycystic ovary morphology are corresponding sequences. Hyper-androgens can be caused by central factors (LH hypersecretion) or peripheral factors. Insulin resistance is the most dominant peripheral factor causing hyperandrogenism. LH and insulin hypersecretion will cause premature luteinization and stop the maturation process in the ovarian follicles. The cessation of the ovarian follicle maturation process in its development will increase the number of follicles and produce a polycystic ovarian morphology.⁷⁻¹¹ This study found the highest average BMI in the phenotype A group compared to other phenotypes, and the most common BMI categories were obesity and overweight. This result is in line with the research by Wiweko et al. that most PCOS were found with obesity (50.4% of respondents). Obesity plays an important role in the pathophysiology of PCOS through insulin resistance.⁷

Relationship between Angiotensin-like-protein-2 levels and Anti-Mullerian Hormone in Polycystic Ovary Syndrome

There are no studies regarding the relationship between ANGPTL2 and AMH directly. From the existing studies, Rahmani et al. examined 26 PCOS samples and 26 controls and found a significant positive correlation between ANGPTL2, insulin and HOMA IR. Wiweko et al. studied 125 PCOS and found a positive correlation between AMH serum and HOMA levels IR. The study by Dai et al. using 102 PCOS samples and 100 controls, found an increased regulation of ANGPTL2 in the serum of obese and non-obese PCOS patients. Based on this explanation, there is a relationship between serum levels of ANGPTL2 and AMH in PCOS.^{7,12,13}

Angiotensin-like-protein-2 is an angiogenic factor produced predominantly by adipose tissue associated with obesity-related-insulin-resistance, insulin-resistance-without-obesity, oocyte development and maturation. Insulin

resistance plays an important role in the occurrence of PCOS through two different pathways. The PI3-kinase pathway mediates metabolic effects (including glycogen formation), and the MAP kinase pathway mediates cell growth and steroidogenic effects. On the other hand, insulin resistance and hyperandrogenemia conditions can occur.¹⁴ Other insulin resistance pathways are related to obesity, which can cause adipocyte hypertrophy, compression of stromal blood vessels, and increased free fatty acids in adipose tissue, which can result in hypoxia. Further, vascular remodelling will stimulate macrophage and inflammation mediators, including ANGPTL2 release into tissues. An increase in ANGPTL2 will trigger chronic low-grade inflammation, exacerbating insulin resistance and hyperandrogenemia. This condition will affect impaired folliculogenesis, which will increase circulating AMH levels.¹⁴

Differences in Angiotensin-like-protein-2 Levels between Phenotypes in Polycystic Ovary Syndrome

This research found the highest average ANGPTL 2 level found in phenotype A group. This study conducted a comparative test of ANGPTL2 serum levels, and there is no significant difference in ANGPTL2 levels between polycystic ovary syndrome phenotypes. In line with a study by Tabata et al., circulating levels of ANGPTL2 are closely related to adiposity, systemic insulin resistance, and inflammation.¹⁵ A study by Dai et al. found increased levels of ANGPTL2 in PCOS in the obesity and without obesity group.¹³ Until now, there is no data regarding ANGPTL2 levels in each PCOS phenotype.

This study found the highest levels of ANGPTL2 and the highest BMI average in phenotype A. Obesity can exacerbate PCOS conditions through the expansion of adipose tissue mass, vascular vasoconstriction and increased release of free fatty acids into the circulation so that the supply of oxygen to adipocytes decreases. Micro-hypoxia induces a chronic inflammatory response, increases the ANGPTL2 serum level, and causes pathological adipose tissue remodelling, resulting in insulin resistance.¹⁵

Differences in Anti-Mullerian Hormone Levels between Phenotypes in Polycystic Ovary Syndrome

The phenotype A group had the highest median AMH level compared to other phenotype groups. Research by Wiweko et al., Gupta et al., Gursu et al., Ozay and Lobo. and Carmina et al. showed that the highest median was in phenotype group A., namely 11.7 ng/ml. 11.68 mg/mL. 9.72 ± 5.6 (2.32-27) ng/mL. 9.17 ± 4.56 ng/mL and 10.2 ± 5 ng/mL.⁷⁻¹¹ This study found significant differences in AMH levels between phenotypes A-B, phenotypes A-C, phenotypes B-C and phenotypes B-D. This study found the most significant difference in AMH levels between phenotypes A and B with a probability value of <0.001 (p <0.05). While between A and D phenotypes and between C and D phenotypes, there were no significant differences. This is in line with research by Gupta et al. that the median difference in AMH levels was significant between phenotype A and phenotype B (p = 0.018).⁹

The increase in AMH serum levels varies in PCOS subgroups, which can be used to differentiate between clinical subgroups because AMH is closely related to PCOM but not to hyperandrogenism.¹⁶ The most significant difference was found between the A and B phenotype groups because phenotype A was the most severe form of phenotype. The phenotype B was a form of PCOS phenotype in which polycystic ovary morphology was not found. The AMH levels reflect the activity of granulosa follicular cells, whose levels increase with a small number of preantral and antral follicles. In PCOS, there is an increase in the number of small preantral and antral follicles due to the influence of insulin resistance and hyperandrogenism. There is no difference between AMH levels in phenotypes A and D and C and D, in which phenotype D is a phenotype without hyperandrogenism. This can be explained by the fact that the hyperandrogenism that occurs is central hyperandrogenism, which is not influenced by the number of follicles in the ovary but by an increase in LH.

CONCLUSION

There is a positive relationship between ANGPTL2 and AMH serum levels.

The ANGPTL2 serum levels did not significantly different, while AMH serum levels were significantly different across the four PCOS phenotypes. The highest values were found in phenotype A.

DISCLOSURE

Author Contribution

All authors have contributed to this research process, including conception and design, analysis and interpretation of the data, article drafting, critical revision of the article for important intellectual content, and final approval.

Funding

This study uses independent funds from researchers.

Conflict of Interest

There are no conflicts of interest to declare.

Ethical Consideration

This research was approved by the Ethics Commission of the Dr. Soetomo General Hospital, Surabaya, Indonesia No. 0486/KEPK/IX/2022.

Acknowledgment

The researcher is very grateful to the institutions, respondents, and research sites for helping carry out this research.

REFERENCES

- Deligeorgiou E, Vrachnis N, Athanasopoulos N, Iliodromiti Z, Sifakis S, Iliodromiti S, Siristatidis C, Creatas G. Mediators of chronic inflammation in polycystic ovarian syndrome. *Gynecol Endocrinol.* 2012;28(12):974-8. doi: [10.3109/09513590.2012.683082](https://doi.org/10.3109/09513590.2012.683082).
- Hashemi AH, Mozdarani H, Mozdarani S. The relationship between hormones level and body mass index with insertion and deletion (D/I) polymorphism of ACE gene in infertile patients with polycystic ovary syndrome. *Bali Med.* 2017;6(1):90-6. doi: [10.15562/bmj.v6i1.382](https://doi.org/10.15562/bmj.v6i1.382).
- Guyansyah A, Wratsangka R, Dhanardono D, Ghazali MF, Edy HJ, Widyatama HG, Kusumaningrum D, Tjahyadi D, Parwanto E. Primary infertility of male and female factors. polycystic ovary syndrome and oligoasthenoeratozoospermia dominate the infertile population in agricultural and industrial areas in Karawang Regency. West Java Province. *Indonesia. Bali Med J.* 2021;10(1):167-73. doi: [10.15562/bmj.v10i1.2281](https://doi.org/10.15562/bmj.v10i1.2281).
- Indonesian Association of Reproductive Endocrinology and Fertility (HIFERI). Indonesian Society of Obstetrics and Gynecology (POGI). Consensus on the management of polycystic ovary syndrome. 2016:1-69.
- Herawati S. Anti-Mullerian Hormone (AMH) as a Novel Marker for Ovarian Function: A Review. *Bali Med J.* 2019;8(2):475-81. doi: [10.15562/bmj.v8i2.1372](https://doi.org/10.15562/bmj.v8i2.1372).
- Abdulah N, Dwifitriana Kouwagam A, Andina and A. Anti-Müllerian Hormone And Inhibin-B Level Profile In Cervical Cancer Patients Treated With Paclitaxel And Cisplatin Combination. *Bali Med J.* 2014;3(2). doi: [10.15562/bmj.v3i2.78](https://doi.org/10.15562/bmj.v3i2.78).
- Wiweko B, Indra I, Susanto C, Natadisastra M, Hestiantoro A. The correlation between serum AMH and HOMA-IR among PCOS phenotypes. *BMC Res Notes.* 2018;11(1):114. doi: [10.1186/s13104-018-3207-y](https://doi.org/10.1186/s13104-018-3207-y).
- Gürsu T, Eraslan A, Angun B. Comparison of body mass index, anti-müllerian hormone and insulin resistance parameters among different phenotypes of polycystic ovarian syndrome. *Gynecology and Obstetrics Clinical Medicine.* 2022;2(4):164-170. doi: [10.1016/j.gocm.2022.10.002](https://doi.org/10.1016/j.gocm.2022.10.002)
- Gupta M, Yadav R, Mahey R, Agrawal A, Upadhyay A, Malhotra N, Bhatla N. Correlation of body mass index (BMI), anti-mullerian hormone (AMH), and insulin resistance among different polycystic ovary syndrome (PCOS) phenotypes - a cross-sectional study. *Gynecol Endocrinol.* 2019;35(11) 970-973. doi: [10.1080/09513590.2019.1613640](https://doi.org/10.1080/09513590.2019.1613640).
- Ozay AC, Emekci Ozay O, Gulekli B. Comparison of Anti-müllerian Hormone (AMH) and Hormonal Assays for Phenotypic Classification of Polycystic Ovary Syndrome. *Ginekol Pol.* 2020;91(11):661-667. doi: [10.5603/GP.a2020.0122](https://doi.org/10.5603/GP.a2020.0122).
- Carmina E, Lobo RA. Comparing Lean and Obese PCOS in Different PCOS Phenotypes: Evidence That the Body Weight Is More Important Than the Rotterdam Phenotype in Influencing the Metabolic Status. *Diagnostics.* 2022;12(10):2313. doi: [10.3390/diagnostics12102313](https://doi.org/10.3390/diagnostics12102313).
- Rahmani E, Akbarzadeh S, Broomand A, Torabi F, Motamed N, Zohrabi M. Serum Levels of Angiopoietin-Like Protein 2 and Obestatin in Iranian Women with Polycystic Ovary Syndrome and Normal Body Mass Index. *J Clin Med.* 2018;7(7):159. doi: [10.3390/jcm7070159](https://doi.org/10.3390/jcm7070159).
- Dai H, Liu F, Lu J, Yang Y, Liu P. miR-124-3p Combined with ANGPTL2 Has High Diagnostic Values for Obese and Nonobese Polycystic Ovary Syndrome. *Int J Endocrinol.* 2022;2022:2155018. doi: [10.1155/2022/2155018](https://doi.org/10.1155/2022/2155018).
- Barber TM, Dimitriadis GK, Andreou A, Franks S. Polycystic ovary syndrome: insight into pathogenesis and a common association with insulin resistance. *Clin Med (Lond).* 2015; 15(6):72-6. doi: [10.7861/clinmedicine.15-6-s72](https://doi.org/10.7861/clinmedicine.15-6-s72).
- Tabata M, Kadomatsu T, Fukuhara S, Miyata K, Ito Y, Endo M, Urano T, Zhu HJ, Tsukano H, Tazume H, Kaikita K, Miyashita K, Iwakaki T, Shimabukuro M, Sakaguchi K, Ito T, Nakagata N, Yamada T, Katagiri H, Kasuga M, Ando Y, Ogawa H, Mochizuki N, Itoh H, Suda T, Oike Y. Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. *Cell Metab.* 2009;10(3):178-88. doi: [10.1016/j.cmet.2009.08.003](https://doi.org/10.1016/j.cmet.2009.08.003).
- Ran Y, Yi Q, Li C. The Relationship of Anti-Mullerian Hormone in Polycystic Ovary Syndrome Patients with Different Subgroups. *Diabetes Metab Syndr Obes.* 2021; 14: 1419-1424. doi: [10.2147/DMSO.S299558](https://doi.org/10.2147/DMSO.S299558).



This work is licensed under a Creative Commons Attribution